公开(公告)号：JP2011130859A

公开(公告)日：2011-07-07

申请号：JP2009291573

申请日：2009-12-23

Applicant: Mitsubishi Electric Corp ,  Shizuoka Prefecture ,  三菱電機株式会社 ,  静岡県

Inventor： YAMAMOTO YUICHI ,  YAMASHITA HARUO

IPC: A61N5/10 ,  G21K1/02 ,  G21K1/087 ,  G21K5/04

Abstract: PROBLEM TO BE SOLVED: To provide a particle beam therapy apparatus capable of accurately irradiating affected tissue with a particle beam by accurately making an irradiation field follow the movement of the affected part.
SOLUTION: The particle beam therapy apparatus includes: an affected part displacement measuring device 9 for measuring the displacement of the affected part caused by the respiration; a steering electromagnet 6 for deflecting the trajectory of the charged particle beam fed from an accelerator 1; an irradiation device 4 for processing the charged particle beam incoming via the steering electromagnet 6 in a prescribed irradiation shape and irradiating the affected part with the processed charged particle beam; a beam position monitor 5 set between the steering electromagnet 6 and the irradiation device 4 for measuring the beam position of the charged particle beam incoming to the irradiation device 4; a steering electromagnet control part 10 having a feedback control function based on the measured beam position for controlling the excitation amount of the steering electromagnet 6 so that the trajectory of the charged particle beam is deflected according to the measured displacement of the affected part; and an irradiation device position control part 4
M for moving the irradiation device 4 according to the displacement of the affected part.
COPYRIGHT: (C)2011,JPO&INPIT

Abstract translation: 要解决的问题：提供一种粒子束治疗装置，其能够通过精确地使照射场跟随受影响部位的运动而精确地照射受影响的组织的粒子束。 解决方案：粒子束治疗装置包括：用于测量由呼吸引起的患部位移的受影响部位位移测量装置9; 用于偏转从加速器1供给的带电粒子束的轨迹的转向电磁铁6; 照射装置4，用于处理以规定的照射形状经由转向电磁体6进入的带电粒子束，并照射处理后的带电粒子束的患部; 设置在转向电磁体6和照射装置4之间的光束位置监视器5，用于测量进入照射装置4的带电粒子束的光束位置; 转向电磁铁控制部分10具有基于测量的光束位置的反馈控制功能，用于控制转向电磁铁6的激励量，使得带电粒子束的轨迹根据被测部位的测量位移偏转; 以及用于根据受影响部位的位移使照射装置4移动的照射装置位置控制部4 M 。 版权所有（C）2011，JPO＆INPIT

公开(公告)号：JP2010265234A

公开(公告)日：2010-11-25

申请号：JP2009119401

申请日：2009-05-18

Applicant: Shizuoka Prefecture ,  静岡県

Inventor： OKAWA KATSUMASA ,  SUGIYAMA NAOTO ,  NAGASAWA TADASHI ,  YUKI AKANE

IPC: A61K8/49 ,  A61K31/522 ,  A61P1/02 ,  A61P11/00 ,  A61P31/04 ,  A61Q11/00 ,  C07D473/08 ,  C07D473/12

Abstract: PROBLEM TO BE SOLVED: To provide an agent for improving oral cavity bacterial flora, inhibiting the proliferation of the bacteria in an oral cavity in order to make a hygienic condition in the oral cavity good, also enabling to keep the dominance of indigenous bacteria by making the proliferation of the indigenous bacteria more predominant in the oral cavity than that of causing bacteria of aspiration pneumonia, and also in considering that it acts in a human oral cavity and in the point of safety, comprising a food component or food raw material.
SOLUTION: This agent for improving the oral cavity bacterial flora is provided by containing caffeine or theophylline as an active ingredient, capable of making the hygienic condition in the oral cavity as good by inhibiting the proliferation of the bacteria, and keeping the dominance of the indigenous bacteria by making the proliferation of the indigenous bacteria more predominant than that of the causing bacteria of the aspiration pneumonia.
COPYRIGHT: (C)2011,JPO&INPIT

Abstract translation: 要解决的问题：为了提供改善口腔细菌菌群的药剂，抑制口腔中细菌的增殖以使口腔中的卫生条件良好，还能够保持土着人的主导地位 细菌通过使本地细菌的增殖在口腔中比在引起吸入性肺炎的细菌中更为主要，并且还考虑到其作用在人的口腔中，并且在安全性方面，包括食物成分或食物原料 材料。 解决方案：通过含有咖啡因或茶碱作为活性成分，能够提高口腔菌群的改善效果，能够通过抑制细菌增殖使口腔中的卫生状况良好，保持优势 的本地细菌通过使本地细菌的增殖比吸入性肺炎引起的细菌的增殖更为主导。 版权所有（C）2011，JPO＆INPIT

公开(公告)号：JP2010211413A

公开(公告)日：2010-09-24

申请号：JP2009055622

申请日：2009-03-09

Applicant: Fujifilm Corp ,  Shizuoka Prefecture ,  富士フイルム株式会社 ,  静岡県

Inventor： HISANAGA TAKAHARU ,  OSAWA SATORU ,  FURUKAWA TAKAYOSHI ,  ENDO MASAHIRO ,  AKIMARU MASAHIRO ,  YAMAGUCHI KEN

IPC: G06F17/30 ,  A61B5/00 ,  G06Q50/22 ,  G06Q50/24 ,  G06T1/00

CPC classification number: G06T7/33 ,  G06F19/321 ,  G06T2207/30004 ,  G16H50/70

Abstract: PROBLEM TO BE SOLVED: To register a case image so that the deviation of featured values can be prevented from being generated in a case image included in the database of a similar image retrieval system for image diagnosis. SOLUTION: Since the registration of the case images to the database is controlled according to the degree of similarity of featured values, it is possible to reduce such possibility that many similar case images appear as retrieval results, and that similar retrieval results disturbing the diagnosis of a person to be diagnosed are shown. COPYRIGHT: (C)2010,JPO&INPIT

Abstract translation: 要解决的问题：为了注册病例图像，使得可以防止在包括在用于图像诊断的类似图像检索系统的数据库中的病例图像中产生特征值的偏差。

解决方案：由于根据特征值的相似度来控制病例图像到数据库的注册，可以减少许多类似病例图像作为检索结果出现的可能性，并且类似的检索结果令人不安 显示诊断患者的诊断。 版权所有（C）2010，JPO＆INPIT

公开(公告)号：JP2009254479A

公开(公告)日：2009-11-05

申请号：JP2008105252

申请日：2008-04-15

Applicant: National Univ Corp Shizuoka Univ ,  Shizuoka Prefecture ,  国立大学法人静岡大学 ,  静岡県

Inventor： SUZUKI TAKAAKI ,  OKADA YOSHIO ,  EKI TSUTOMU ,  SAKURAGAWA TOMOHITO ,  OTA YUKIHIRO ,  KAWAHITO SHOJI

IPC: A61M21/02 ,  A61M21/00 ,  G01J1/00 ,  G01J1/04 ,  G01J1/42

Abstract: PROBLEM TO BE SOLVED: To solve the problem that there is yet no method capable of easily evaluating an actual light environment. SOLUTION: The light environment including a plurality of light sources to be evaluated is photographed by relative spectral sensitivity and melatonin secretion suppression sensitivity to acquire photographed images of respective sensitivities. In the photographed images of the respective sensitivities, light source regions of the respective light sources are extracted and pixel values of pixels within the light source regions of the respective light sources are multiplied to calculate a brightness amount under the relative spectral sensitivity related to the respective light sources and a melatonin secretion suppressive component amount under the melatonin secretion suppression sensitivity, light properties of the respective light sources are estimated on the basis of the brightness amount and the melatonin secretion suppressive component amount, and the light environment is evaluated on the basis of the estimation. COPYRIGHT: (C)2010,JPO&INPIT

Abstract translation: 要解决的问题：为了解决没有能够容易地评估实际的光环境的方法的问题。 解决方案：通过相对光谱灵敏度和褪黑激素分泌抑制灵敏度拍摄包括要评估的多个光源的光环境，以获取各自灵敏度的拍摄图像。 在各个感光度的拍摄图像中，提取各个光源的光源区域，并且将各个光源的光源区域内的像素的像素值相乘以计算与各个光源相关的相对光谱灵敏度下的亮度量 褪黑素分泌抑制敏感性下的光源和褪黑激素分泌抑制成分量，基于亮度量和褪黑激素分泌抑制成分量来估计各光源的光特性，基于 估计。 版权所有（C）2010，JPO＆INPIT

公开(公告)号：JP2009254365A

公开(公告)日：2009-11-05

申请号：JP2009079369

申请日：2009-03-27

Applicant: Shizuoka Prefecture ,  静岡県

Inventor： FUKUDA YORIKANE ,  MOCHIZUKI TORU ,  OSHIMA KEIICHI

IPC: C12N15/09 ,  C12Q1/02 ,  C12Q1/68

Abstract: PROBLEM TO BE SOLVED: To provide a method for identifying a gene usable as the markers of various cancers including highly metastatic stomach cancer and judging the cancers, to provide a kit therefor, and to provide a method for screening a cancer inhibitor. SOLUTION: A highly metastatic human stomach cancer culture cell strain having a high peritoneum metastatic ability is produced from a human stomach cancer culture cell strain, and the mRNA expressions of the strain before and after the acquisition of the metastatic ability were comprehensively compared and examined with exon microarray. Consequently, a new exon sequence of BHMT (betaine-homocysteine methyltransferase), EPSTI1 (epithelial stromal interaction 1, (breast)), and NEBL (nebulette), a gene participating in cell adhesion is identified. In addition, it is found that the new splicing variants of the BHMT, EPSTI1 and NEBL are expressed in stomach cancer cells and in large intestinal cancer cells. COPYRIGHT: (C)2010,JPO&INPIT

Abstract translation: 待解决的问题：提供一种用于鉴定可用作包括高度转移性胃癌和判断癌症的各种癌症的标志物的基因的方法，以提供其用途，并提供筛选癌症抑制剂的方法。 解决方案：从人胃癌培养细胞株产生具有高腹膜转移能力的高度转移性的胃癌培养细胞株，并且全面比较了获得转移能力前后的菌株的mRNA表达 并用外显子微阵列检查。 因此，鉴定了参与细胞粘附的基因的BHMT（甜菜碱 - 高半胱氨酸甲基转移酶），EPSTI1（上皮间质相互作用1（乳房））和NEBL（nebulette）的新外显子序列。 此外，发现BHMT，EPSTI1和NEBL的新剪接变体在胃癌细胞和大肠癌细胞中表达。 版权所有（C）2010，JPO＆INPIT

公开(公告)号：JP2009254364A

公开(公告)日：2009-11-05

申请号：JP2009079347

申请日：2009-03-27

Applicant: Shizuoka Prefecture ,  静岡県

Inventor： FUKUDA YORIKANE ,  MOCHIZUKI TORU ,  OSHIMA KEIICHI

IPC: C12N15/09 ,  C12Q1/68

Abstract: PROBLEM TO BE SOLVED: To provide a method for judging highly metastatic stomach cancer, to provide a kit therefor, and to provide a method for screening a highly metastatic stomach cancer inhibitor. SOLUTION: A highly metastatic human stomach cancer culture cell strain having a high peritoneum metastatic ability is produced from a human stomach cancer culture cell strain, and the mRNA expressions of the strain before and after the acquisition of the metastatic ability were comprehensively compared and examined with exon microarray. Consequently, it is found that a new exon sequence of DNAJC12 (DnaJ (Hsp40) homolog, subfamily C, member 12), ULBP1 (UL16 binding protein 1), and XAF1 (XIAP associated factor-1) is identified, and a splicing variant containing a region encoded by the new exon DNA sequences is specifically strongly expressed in the high metastatic strain. In addition, it is found that the new variant of ULBP1 is expressed not only in stomach cancer cells but also in pancreatic cancer, large intestinal cancer or breast cancer cells. COPYRIGHT: (C)2010,JPO&INPIT

Abstract translation: 待解决的问题：提供一种用于判断高度转移性胃癌的方法，以提供其用途，并提供筛选高度转移性胃癌抑制剂的方法。 解决方案：从人胃癌培养细胞株产生具有高腹膜转移能力的高度转移性的胃癌培养细胞株，并且全面比较了获得转移能力前后的菌株的mRNA表达 并用外显子微阵列检查。 因此，发现鉴定出DNAJC12（DnaJ（Hsp40）同系物，亚族C，成员12），ULBP1（UL16结合蛋白1）和XAF1（XIAP相关因子-1）的新外显子序列，以及剪接变体 含有由新的外显子DNA序列编码的区域在高转移性菌株中特别强烈表达。 此外，发现ULBP1的新变体不仅在胃癌细胞中表达，而且在胰腺癌，大肠癌或乳腺癌细胞中表达。 版权所有（C）2010，JPO＆INPIT

公开(公告)号：JP2009240428A

公开(公告)日：2009-10-22

申请号：JP2008088645

申请日：2008-03-28

Applicant: Fujipharma Co Ltd ,  Shizuoka Prefecture ,  フジファルマ株式会社 ,  静岡県

Inventor： NAKAYAMA HIROSHI ,  NAGATA YASUSHI ,  OBA MASAHARU ,  TAMIZU SEIICHI ,  WATANABE SETSUO

IPC: A61M5/168

Abstract: PROBLEM TO BE SOLVED: To provide an inexpensive intravenous drip measuring system, which is miniaturized and allows a nurse or the like to easily and accurately perform measuring work. SOLUTION: The intravenous drip measuring system comprises a sensor slave unit 3 attachable to the intravenous drip fall part 2 of a free fall type intravenous drip set 1 and a mobile master unit 4 capable of wireless communication with the sensor slave unit 3. The sensor slave unit 3 is provided with a sensor part 5 for detecting or measuring the dripping or the number of drops of infusion freely falling at the intravenous drip fall part 2 within the prescribed measurement time, and an RFID tag part for wirelessly transmitting slave unit identification information stored beforehand the dripping or the number of drops which is detected or measured as dripping signals. The mobile master unit 4 is provided with an RFID reader part for communicating with the RFID tag part by electromagnetic induction or electromagnetic coupling and receiving the dripping signals, an operation control part for calculating an intravenous drip speed on the basis of the received dripping signals, and a display part 18 for displaying the calculated intravenous drip speed. COPYRIGHT: (C)2010,JPO&INPIT

Abstract translation: 要解决的问题：为了提供一种便宜的静脉滴注测量系统，其小型化并且允许护士等容易且准确地执行测量工作。 解决方案：静脉滴注测量系统包括可附接到自由落体式静脉滴注装置1的静脉滴注部分2的传感器从单元3和能够与传感器从单元3无线通信的移动主单元4。 传感器从单元3设置有用于检测或测量在规定测量时间内自动落在静脉滴落部分2处的滴液滴数或滴数的传感器部分5以及用于无线传送从属单元的RFID标签部分 识别信息预先存储了作为滴水信号被检测或测量的滴液量或滴数。 移动主控单元4设置有RFID读取器部分，用于通过电磁感应或电磁耦合与RFID标签部分进行通信，并接收滴落信号;操作控制部分，用于根据接收的滴液信号计算静脉滴注速度; 以及显示计算出的静脉滴注速度的显示部18。 版权所有（C）2010，JPO＆INPIT

公开(公告)号：JP2009155146A

公开(公告)日：2009-07-16

申请号：JP2007333652

申请日：2007-12-26

Applicant: Ascam:Kk ,  Shizuoka Prefecture ,  株式会社アスカム ,  静岡県

Inventor： YAMASHITA RIE ,  MATSUURA HIRONAO ,  YOKOYAMA KIMIYA

IPC: C01B31/10 ,  A61L9/01 ,  A61L9/16 ,  B01J20/20

Abstract: PROBLEM TO BE SOLVED: To provide activated carbon selectively adsorbing and removing volatile organic material such as toluene having small molecule diameter and causing sick house syndrome, malodor or the like while keeping fragrance of terpene or the like.
SOLUTION: The activated carbon is provided with a slit-like micropore 11 having slit-like shaped opening 11a having ≤0.8 nm slit width L1, wherein the distribution of the slit width L1 has a peak substantially only in 0.4-0.6 nm in the measurement by a t-plot method by nitrogen adsorption, the specific surface area of total pores is ≥400 m
2 /g to the mass of carbonized material and the ratio of the specific surface area of the slit-like micropore is ≥85% to the specific surface area of total pores.
COPYRIGHT: (C)2009,JPO&INPIT

Abstract translation: 待解决的问题：提供活性炭选择性吸附和除去挥发性有机物质如具有小分子直径的甲苯，并引起病房综合征，恶臭等，同时保持萜烯等的香味。 解决方案：活性炭设置有狭缝状微孔11，狭缝状微孔11具有狭缝宽度L1≤0.8nm的狭缝状开口11a，其中狭缝宽度L1的分布基本上仅在0.4-0.6nm 在通过氮吸附的t绘图法的测量中，总孔的比表面积相对于碳化材料的质量为≥400m2 / SP / g，并且比表面积的比例 裂缝状微孔相对于总孔的比表面积≥85％。 版权所有（C）2009，JPO＆INPIT

公开(公告)号：JP2009122019A

公开(公告)日：2009-06-04

申请号：JP2007297783

申请日：2007-11-16

Applicant: Shizuoka Prefecture ,  静岡県

Inventor： ASAI AKIYOSHI ,  SAWADA JUNICHI ,  UNNO YUKA

IPC: G01N33/50 ,  C12N15/09 ,  G01N33/15 ,  G01N33/543 ,  G01N33/566

Abstract: PROBLEM TO BE SOLVED: To provide a method of screening a substance inhibiting interaction between human surviving protein and partner protein interactive thereto (Smac protein, INCENP protein, human surviving protein) with high throughput and high sensitivity.
SOLUTION: The screening method includes the following steps (a) to (d): (a) a first reaction liquid preparation step to react biotinylated human surviving protein and tag-fused partner protein in the presence or absence of a test material within a buffer liquid; (b) a second reaction liquid preparation step to further react by adding streptavidin-donor beads and nickel chelate-acceptor beads or anti-GST-acceptor beads to the first reaction liquid; (c) a measuring/comparing step to measure and compare the interaction between the nickel chelate-acceptor beads or anti-GST-acceptor beads bonded tag-fused partner protein by a chemical amplification-type luminescence proximity homogeneous assay (AlphaScreen) method; and (d) an evaluation step to evaluate the test material as an human surviving/partner protein interaction inhibiting substance when the signal measured by the AlphaScreen method decreases comparing the case adding the test material with the case not adding.
COPYRIGHT: (C)2009,JPO&INPIT

Abstract translation: 要解决的问题：提供一种以高通量和高灵敏度筛选抑制人存活蛋白质与其相互作用的伴侣蛋白（Smac蛋白，INCENP蛋白，人存活蛋白）之间的相互作用的物质的方法。 解决方案：筛选方法包括以下步骤（a）至（d）：（a）在存在或不存在测试材料的情况下使生物素化的人存活蛋白质和标签融合的配对蛋白质反应的第一反应液体制备步骤 在缓冲液内; （b）第二反应液体制备步骤，通过向第一反应液体中加入链霉亲和素供体珠和镍螯合受体珠或抗GST受体珠进一步反应; （c）测量/比较步骤，通过化学扩增型发光接近均质测定（AlphaScreen）方法来测量和比较键合标记融合配偶体蛋白的镍螯合受体珠或抗GST受体珠之间的相互作用; 和（d）当通过AlphaScreen方法测量的信号比较添加测试材料的情况与不添加的情况相比时，评价测试材料作为人类存活/伴侣蛋白相互作用抑制物质的评估步骤。 版权所有（C）2009，JPO＆INPIT

公开(公告)号：JP2009084278A

公开(公告)日：2009-04-23

申请号：JP2008234663

申请日：2008-09-12

Applicant: Shizuoka Prefecture ,  Sunstar Inc ,  サンスター株式会社 ,  静岡県

Inventor： NISHIJIMA NANAE ,  FUJII AKIKO ,  FUJISAWA KOICHI ,  OTA YOJIRO

IPC: A61K47/36 ,  A61K31/047 ,  A61K47/04 ,  A61P1/02

Abstract: PROBLEM TO BE SOLVED: To provide an oral composition having improved preservation stability, a micro-gel preparation having excellent ratainability in the mouth. SOLUTION: Micro-gel particles are prepared by adding gellan gum of 0.3 to 0.4% by weight as a gelling agent and 1 to 6 mmol of a divalent metal ion per 1 g of the gellan gum as a crosslinking agent. The oral composition having excellent retainability in the mouth and improved preservation stability such as syneresis and appearance is characterized by being produced by constructing a preparation with the assembly of the micro-gel particles. COPYRIGHT: (C)2009,JPO&INPIT

Abstract translation: 待解决的问题：为了提供具有改善的保存稳定性的口服组合物，在口腔中具有优异的可溶性的微凝胶制剂。 解决方案：通过加入0.3至0.4重量％的凝胶胶作为胶凝剂和1至6mmol二价金属离子/ 1g作为交联剂的结冷胶，制备微凝胶颗粒。 具有优异的口腔保持性和提高的保存稳定性如脱水收缩和外观的口腔组合物的特征在于通过构建具有微凝胶颗粒的组装的制剂来制备。 版权所有（C）2009，JPO＆INPIT